Stephen V Liu, MD· @StephenVLiu · X·· 3 天前评分45
正文 · 原文
#ESMO26 Dr. @peters_solange presents phase 3 study of sigvotatug vedotin (SV, integrin beta-6 ADC) vs docetaxel in previously treated non-squamous NSCLC. No difference in survival. Some signal in driver-negative NSCLC in 2L setting (vs 3L). #ESMOAmbassadors
64 浏览 · 3 赞 · 2 转发 · 1 回复
帖内回复
- Jose Fernando Moura, PhD@FernandoOnco
@StephenVLiu @peters_solange @myESMO The signs is so thin like a jamon slice
来源：Stephen V Liu, MD · x.com